Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27648642 | 0.88 | PTGS1 (0.44) | PTGS1PTGS2KMT2AALOX5KDM4E | |
| SCHEMBL13366369 | 0.85 | CA12 (0.51) | PTGS1PTGS2KMT2AMEN1HTT | |
| SCHEMBL3187719 | 0.81 | MEN1 (0.46) | PTGS1PTGS2KMT2AMEN1HTT | |
| SCHEMBL1208429 | 0.79 | PTGS1 (0.56) | PTGS1PTGS2KMT2AMEN1HTT | |
| SCHEMBL545919 | 0.78 | MEN1 (0.46) | KMT2AMEN1HTTALOX5KDM4E | |
| SCHEMBL28804341 | 0.78 | ALDH1A1 (0.50) | KMT2AMEN1HTTALOX5KDM4E | |
| SCHEMBL432482 | 0.77 | MEN1 (0.66) | PTGS1PTGS2KMT2AMEN1HTT | |
| SCHEMBL20839505 | 0.77 | MEN1 (0.48) | PTGS2KMT2AMEN1HTTALOX5 | |
| SCHEMBL416748 | 0.77 | MAPT (0.56) | PTGS1PTGS2KMT2AMEN1HTT | |
| SCHEMBL9160812 | 0.76 | RXRA (0.46) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1768050-A | Benzopyran compounds for the treatment of inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | disclosed |
| US-20050101563-A1 | Method and compositions for the treatment and prevention of pain and inflammation | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | US | disclosed |
| US-20050085478-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050085479-A1 | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080083-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-04-14 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085479-A1 | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury | CRH, CRHR2, CRHR1 | PTGS1 9/4885PTGS2 6/4885KMT2A 4349/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | PTGS1 16/4885PTGS2 9/4885KMT2A 4040/4885 |
| US-20050085478-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage | PTGS2, PTGS1, PTGER2 | PTGS1 2/4885PTGS2 1/4885KMT2A 3304/4885 |
| US-20050101563-A1 | Method and compositions for the treatment and prevention of pain and inflammation | PTGES2, PTGS2, PTGS1 | PTGS1 3/4885PTGS2 2/4885KMT2A 3732/4885 |
| US-20050080083-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage | AGTR2, AGTR1, ACE2 | PTGS1 20/4885PTGS2 7/4885KMT2A 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.